Inmolecule NanotechXPAR:MLINA 6 Current Ratio is 2.09 as of Dec. 2024, which is 7% below its 10-year median of 2.25. GuruFocus rates XPAR:MLINA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Inmolecule Nanotech ranks worse than 67.42% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Inmolecule Nanotech's current ratio for the quarter that ended in Dec. 2024 was 2.09.
Inmolecule Nanotech has a current ratio of 2.09. It generally indicates good short-term financial strength.
The historical rank and industry rank for Inmolecule Nanotech's Current Ratio or its related term are showing as below:
XPAR:MLINA'
s Current Ratio Range Over the Past 10 Years
Min: 2.09 Med: 2.25 Max: 2.4
Current: 2.09
During the past 2 years, Inmolecule Nanotech's highest Current Ratio was 2.40. The lowest was 2.09. And the median was 2.25.
XPAR:MLINA's Current Ratio is ranked worse than 67.42% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs XPAR:MLINA: 2.09
Inmolecule Nanotech (XPAR:MLINA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Inmolecule Nanotech Current Ratio Related Terms
Inmolecule Nanotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Inmolecule Nanotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inmolecule Nanotech Current Ratio Chart
Inmolecule Nanotech Annual Data
Trend
Dec23
Dec24
Current Ratio
2.40
2.09
Inmolecule Nanotech Semi-Annual Data
Dec23
Dec24
Current Ratio
2.40
2.09
XPAR:MLINA vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Inmolecule Nanotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inmolecule Nanotech Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Inmolecule Nanotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inmolecule Nanotech (XPAR:MLINA) has a Current Ratio of 2.09 as of Dec. 2024. This is near median its historical median of 2.25. Over the past decade, Inmolecule Nanotech's Current Ratio has ranged from 2.09 to 2.40. According to the industry distribution chart, Inmolecule Nanotech ranks #952 out of 1412 companies in the Biotechnology industry, placing it in the top 67.4%.
Is Inmolecule Nanotech's Current Ratio too high?
Inmolecule Nanotech's current Current Ratio of 2.09 is near median its 10-year median of 2.25. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 2.40. The Biotechnology industry median Current Ratio is 3.89. Inmolecule Nanotech's value of 2.09 is 46.3% below this industry median. Based on the distribution chart, Inmolecule Nanotech ranks #952 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inmolecule Nanotech has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inmolecule Nanotech ranks #952 out of 1412 companies for Current Ratio. This places Inmolecule Nanotech in the lower half of its industry. The industry median Current Ratio is 3.89. Inmolecule Nanotech's value of 2.09 is 46.3% below this benchmark. Historically, Inmolecule Nanotech's own Current Ratio has ranged from 2.09 to 2.40 over the past decade. While the company's 10-year median is 2.25 vs. the industry median of 3.89, Inmolecule Nanotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inmolecule Nanotech's current Current Ratio of 2.09 is 46.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inmolecule Nanotech's current Current Ratio is 2.09, which is near median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current Current Ratio of 2.09. The current Current Ratio is 2.09, which is near median its 10-year median of 2.25 and 46.3% below the Biotechnology industry median of 3.89. Inmolecule Nanotech's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current Current Ratio is 2.09 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLINA has been successfully added to your 